Heart rate management: A therapeutic goal throughout the cardiovascular continuum

European Heart Journal, Supplement

Volumn 10, Issue F, 2008, Pages

  Zamorano, Jose Luis ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cardiovascular disease continuum; Coronary artery disease; Heart rate; Risk factors

Indexed keywords

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; HEART RATE; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; STRESS; VASCULAR ENDOTHELIUM;

EID: 77949394274     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sun022     Document Type: Review

References (30)

1. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plitzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved outcome. Part I. Pathophysiology and clinical trial evidence (Risk factors through stable coronary artery disease). Circulation 2006;114:2850-2870.
2. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved outcome. Part II. Clinical trial evidence (Acute coronary syndromes through renal disease. Circulation 2006;114:2871-2891.
3. Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-749.
4. Kannel WB, Kannel CE, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality in the Framingham study. Am Heart J 1987; 113:1489-1494.
5. Seccareccia F, Pannozzo F, Dima F, Minoprio A, Menditto A, Lo Noce C, Giampaoli S; Malattie Cardiovascolari Aterosclerotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001;91:1258-1263.
6. Jouven X, Empana JP, Schwarz PJ, Desnos M, Courbon D, Ducimetière P. Heart rate profile during exercise as a predictor of sudden death. N Engl J Med 2005;352:1951-1958.
7. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-897.
8. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
9. Aboyans V, Criqui MH. Can we improve cardiovascular risk prediction beyond risk equations in the physician's office? J Clin Epidemiol 2006; 59:547-558.
10. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-830.
11. Lévy S, Guize L. Heart rate, a major prognostic factor of cardiovascular risk. Therapie 2006;61:115-119.
12. Palatini P. Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms. Drugs 2007; 67(Suppl. 2):3-13.
13. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A; European Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006;24:603-610.
14. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. Int J Cardiol 2008;126: 302-312.
15. Kop WJ, Verdino RJ, Gottdiener JS, O'Leary ST, Bairey Merz CN, Krantz DS. Changes in heart rate and heart rate variability before ambulatory ischemic events. J Am Coll Cardiol 2001;38:742-749.
16. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984;226:180-182.
17. Yamamoto E, Lai ZF, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Ito T, Ogawa H, Kim-Mitsuyama S. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006;24:2057-2069.
18. Guth BD, Heusch G, Seitelberger R, Ross J Jr. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 1987;60:738-746.
19. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.
20. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007;28:3012-3019.
21. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101:865-869.
22. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801.
23. f current inhibition with ivabradine. Drugs 2004;64:1757-1765.
24. f inhibitor, in stable angina. A randomized, double blind, multi-centered, placebo-controlled trial. Circulation 2003;107:817-823.
25. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536.
26. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multi-centre, noninferiority trial. Drugs 2007;67:393-405.
27. f inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003;100:149-155.
28. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109: 1674-1679.
29. Fox K, Ferrari R, Tendera M, Steg PG, Ford I. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006;152:860-866.
30. Current controlled trials. ISRCTN70429960: effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study. http://www.controlled- trials.com/ISRCTN70429960/ivabradine.